Trials / Not Yet Recruiting
Not Yet RecruitingNCT04609241
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
Clinical Trial for the Safety and Efficacy of Murine CD79b CAR-T Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A study of CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
Detailed description
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 72 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety.
Conditions
- Relapsed and/or Refractory Acute Lymphoblastic Leukemia
- Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD79b CAR-T Cells | Each subject receive CD79b CAR-Tcells by intravenous infusion |
Timeline
- Start date
- 2020-11-15
- Primary completion
- 2023-11-15
- Completion
- 2026-11-15
- First posted
- 2020-10-30
- Last updated
- 2020-10-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04609241. Inclusion in this directory is not an endorsement.